Natrecor
ORG
Natrecor
Scios has struggled since sales of its flagship drug, the heart failure treatment Natrecor, began declining last year over safety concerns. Natrecor sales reached $400 million in 2004. But the company has said that sales declined significantly after outside medical researchers raised questions last year about whether the treatment increased the risk of kidney problems and death. Scios is also the subject of a Justice Department investigation into whether it improperly promoted Natrecor for an unapproved use, according to company disclosures to the Securities and Exchange Commission.